icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
uYWVRaYGN2SHhpC8